2024 会议热点速递——EMBARK 研究数据解读

参考文献

[1] Shore ND, et al. EMBARK: A PHASE 3 RANDOMIZED STUDY OF ENZALUTAMIDE OR PLACEBO PLUS LEUPROLIDE ACETATE AND ENZALUTAMIDE MONOTHERAPY IN HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER. 2023 AUA LBA02-09.

[2] Freedland SJ, Sieber PR, Gleave M et al. Enzalutamide combination treatment (tx) suspension 

in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK. Journal of Clinical Oncology 2024; 42: 156-156.

[3] Shore ND, Sieber PR, Gleave M et al. Outcomes of men with high-risk biochemically recurrent 

prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study. Journal of Clinical Oncology 2024; 42: 15-15.

[4] Freedland SJ, et al. EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL). 2024 ASCO 5005.